Brief: Cereno Scientific Preclinical Data Conclude Candidate CS585 Provides New Option Of Activating IP Receptor

Cereno Scientific AB

12/12/2023 13:06

Dec 12 (Reuters) - Cereno Scientific AB  CRNOSb.ST :
    * PRECLINICAL DATA CONCLUDE THAT DRUG CANDIDATE CS585 PROVIDES A NEW OPTION OF ACTIVATING IP
RECEPTOR TO DECREASE PLATELET REACTIVITY
    * CS585 COULD REPRESENT FIRST VIABLE OPTION FOR TARGETING IP RECEPTOR ON PLATELETS FOR
PRIMARY
INHIBITION OF THROMBOSIS WITH A REDUCED RISK OF BLEEDING

Source text for Eikon:  ID:nWkr99BxQR 
Further company coverage:  CRNOSb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))